BAO PHARMA-B's stock surged 5.62% during intraday trading on Monday, significantly outperforming a generally weak biotechnology sector.

The rally appears driven by multiple positive company-specific developments. Chairman and controlling shareholder group member Dr. Liu Yanjun announced a plan to increase holdings in the company through open market transactions, signaling strong confidence in its long-term prospects. Furthermore, the company received market approval from the National Medical Products Administration for its injectable human hyaluronidase, adding a new commercialized product to its portfolio.

Investor sentiment was also bolstered by the approval of a share repurchase authorization for up to 10% of the issued H shares at a recent shareholders' meeting, with the company assuring that the buyback funds are compliant and will not impact normal operations.